Buserelin
- Generic Name
- Buserelin
- Brand Names
- Suprefact
- Drug Type
- Small Molecule
- Chemical Formula
- C60H86N16O13
- CAS Number
- 57982-77-1
- Unique Ingredient Identifier
- PXW8U3YXDV
- Background
Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
- Indication
Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
- Associated Conditions
- Endometriosis, Stage D2 Prostatic carcinoma
- Associated Therapies
- -
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles
- Conditions
- Interventions
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- Andros Day Surgery Clinic
- Target Recruit Count
- 194
- Registration Number
- NCT01816789
- Locations
- 🇮🇹
ANDROS Day Surgery Clinic, Palermo, Sicily, Italy
Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Yazd Medical University
- Target Recruit Count
- 159
- Registration Number
- NCT01213147
- Locations
- 🇮🇷
Yazd Research and Clinical Center for Infertility, Yazd, Iran, Islamic Republic of
Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2009-01-28
- Lead Sponsor
- Yazd Research & Clinical Center for Infertility
- Target Recruit Count
- 200
- Registration Number
- NCT00830492
- Locations
- 🇮🇷
Yazd Research and Clinical Center For Infertility, Yazd, Iran, Islamic Republic of
Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2009-01-15
- Lead Sponsor
- Yazd Research & Clinical Center for Infertility
- Target Recruit Count
- 2
- Registration Number
- NCT00823602
- Locations
- 🇮🇷
Yazd Research and Clinical Center For Infertility, Yazd, Iran, Islamic Republic of
Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Yazd Research & Clinical Center for Infertility
- Target Recruit Count
- 500
- Registration Number
- NCT00823121
- Locations
- 🇮🇷
: Research and clinical center for infertility, Yazd, Iran, Islamic Republic of
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 48
- Registration Number
- NCT00651326
- Locations
- 🇨🇦
McGill University - Dept. Oncology, Montreal, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 25
- Registration Number
- NCT00054106
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.